electroCore Expands Intellectual Property Portfolio With Two New Patents, "No. 11,944,815" And "No. 11,944,807"
Portfolio Pulse from Benzinga Newsdesk
electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine company, announced the receipt of two new patents from the USPTO, enhancing its intellectual property in non-invasive vagus nerve stimulation (nVNS) technology. The patents, issued on April 2, 2024, cover a system for nerve stimulation via a mobile device and methods for treating central nervous system disorders with electrical impulses.
April 02, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
electroCore received two patents for its nVNS technology, focusing on mobile device nerve stimulation and treating CNS disorders.
The issuance of these patents significantly strengthens electroCore's intellectual property portfolio, potentially leading to new product developments and market opportunities. This could enhance investor confidence and attract attention to ECOR's innovative approach to treating CNS disorders, likely resulting in a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100